Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc., as noted in the metadata request) on February 3, 2011. The report discloses the issuance of a press release regarding financial results for the fiscal quarter ended December 31, 2010.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing does not provide specific data to compare current period results against prior comparable periods. It serves solely as a notification that results for the quarter ended December 31, 2010, have been announced.
Guidance, Outlook, and Risks
The filing includes a standard "safe harbor" statement regarding forward-looking information. Management commentary and future projections are subject to significant risks and uncertainties, including:
- Changes in regulatory clinical and guideline developments.
- Insufficient scientific data to meet regulatory standards or failure to receive required approvals.
- Inability to replicate clinical results in actual patient settings.
- Challenges to patent protection, including invalidation or circumvention by competitors.
- Market size expectations not being met or failure to penetrate targeted markets.
- Insufficient revenues to fund further development and clinical studies.
- Failure to meet future capital needs or obtain additional funding.
- Uncertainties regarding product formulations and diverse regulatory requirements across different countries.
The company disclaims any obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release) referenced in this filing.
- Confirm the company name is Oculus Innovative Sciences, Inc., as the metadata request incorrectly listed Sonoma Pharmaceuticals, Inc.
- Review the company's most recent Form 10-K for the year ended March 31, 2010, for detailed risk factors.
- Assess the company's current cash runway and capital requirements given the stated risk of insufficient funding for development.